The effect of detailed information concerning the side effects of vaccination on medical consultations after influenza vaccination;Der einfluss intensiver aufklärung zu impfnebenwirkungen auf die ärztliche beratungstätigkeit nach grippeschutzimpfung

Arbeitsmedizin Sozialmedizin Umweltmedizin

Volumn 41, Issue 11, 2006, Pages 502-508

  Schneider, Michael ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Influenza; Vaccination; Vaccination information; Vaccination reaction

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CONSULTATION; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INFLUENZA VACCINATION; MEDICAL INFORMATION; PATIENT ASSESSMENT; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 33751560445     PISSN: 09446052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Acazana M, Sendefar JM.Economic costs of influenza-related work absentism. Value Health 2003;6(2):107-115
2. Ahmed, AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995;346:591-595
3. Arbeitsgemeinsch.Influenza. Saisonabschlussbericht 2004/2005 http://influenza.rki.de/agi/index.html?c=saisonbericht.
4. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982;142:85-89
5. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-1663
6. Dimicheli V, Jefferson T, Rivetti D et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957-1030
7. Gross PA, Hermogenes AW, Sacks HS et al. Efficacy of influenza vaccine in elderly persons:a meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527
8. Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997;29:181-185
9. Mauskopf JA, Cates SC, Griffin AD. A pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics 1999; 16 (Suppl 1):73-84
10. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenca in healthy adulescents and adults. Clin Infect Dis 2001;33(11):1879-1885
11. Müller D, Wutzler P, Szucs TD. Influenza vaccination coverage rates in Germany: a population-based cross-sectional analysis of the reasons 2002/2003 and 2003/2004. Med Klin (Munich) 2005;100:6-13
12. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002;13:72-78
13. Neuzil KM, Edwards KM. Influenza vaccines in children. Semin Pediatr Infect Dis 2002;13:174-181
14. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749-759
15. Nichol KL, Mallon KP. Cost benefit of influenza vaccination in healthy working adults: an economic analysis based on the results of a clinical trial of the trivalent live attenuated influenza vaccine. Vaccine 2003; 21(17-18): 2207-17
16. RKI. Teilnahme an Influenza- und Pneumokokken - Schutzimpfungen (2001/2002). Epid Bull 2002;16:127-131
17. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44: 11-15
18. Szucs T, Behrins M. Public health costs of influenza in Germany 1996 - a cost-of-illness analysis. Med Klin 1996;96 (2):63-70
19. Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals: a randomized controlled trial. JAMA 1999;281:908-913